ClinicalTrials.gg
CompletedNCT02202616POWERUpdated Jul 2, 2019Results posted

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)

A Phase 4 interventional study of Glycopyrronium /Indacaterol maleate in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
401
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
27th of 73
401 · median 152
Started
2014
with 8 others
Phase 4
11 of 73
1 open now
Registered
41st of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 27th largest by enrollment, is one of 9 that started in 2014, is one of 11 in phase 4, and was the 41st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed dose combinations fluticasone propionate/salmeterol. Only patients for whom the physician has decided to change treatment due to lack of efficacy will be eligible to be enrolled in the study.

Also will evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD,
  • QVA149,
  • Tiotropium,
  • FDC,
  • GlycOpyrronium With IndacatERol,
  • POWER
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient diagnosed and treated for moderate to severe according to the Global Initiative for Chronic Obstructive Lung Disease according to physician's assessment
  • Smoking history of > 10 pack - years.
  • On-going treatment with tiotropium or fixed dose combination of LABA/ICS, specifically combinations fluticasone propionate/salmeterol for a minimum of three months but demonstrating persistence of symptoms indicating change of treatment to combination therapy **using a CAT score > 10.
  • Treatment with QVA149 is indicated as per the product monograph and appropriate for the patient as per the judgment of the treating physician.
  • Patient has signed agreeing to participate in the study and undergo the study treatments and allowing the use of their data for the purposes of the study.
  • Patient is expected to be available for 16 weeks after study enrolment

    • Assessed as per routine care or as documented in the patient's chart. ** As determined and decided by the treating physician prior to enrolment of the patient in the study.

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.

  • Patients not willing to sign an .
  • Patient on maintenance treatment including triple therapy (LABA +LAMA+ICS) for
  • Patients with a diagnosis of asthma or history of asthma.
  • Patients who have had two or more moderate to severe exacerbations during the last 12 months prior to study enrolment. A moderate COPD exacerbation is defined by requirement for treatment with systemic or antibiotics or both. A severe COPD exacerbation is defined by hospitalization, including an emergency room visit of longer than 24 h.
  • Patients who had an exacerbation within the previous 6 weeks to enrolment.
  • Patients who as per physician clinical judgment will require ICS treatment co-administered with QVA149 during the study period.
  • Patients with other chronic respiratory conditions that may affect the outcome of treatment including but not limited to lung cancer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Other
    ULTIBRO BREEZHALER

    Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).

    Drug: Glycopyrronium /Indacaterol maleate

Interventions

  • DrugGlycopyrronium /Indacaterol maleate

    Drug pages: Glycopyrrolate · Indacaterol maleate

    Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)

    Primary end points: To evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 with tiotropium monotherapy; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks. and to evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 while on treatment with FDC of fluticasone propionate/salmeterol; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks.

    Time frame: 16 weeks study

Secondary outcomes

  1. Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4

    Portable spirometers will be provided to investigators and they will use this device for all of their patient measurements of FEV1 during the trial

    Time frame: Baseline, week 4

  2. Single Point and Change in Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI)

    A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). BDI/TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. The BDI was assessed at Baseline, whereas the TDI was assessed at Week 4 and Week 16.

    Time frame: Baseline, Week 4, week 16

  3. Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Questionnaire (CAT)

    The CAT is an 8 item questionnaire that assesses the impact of COPD on the patient's functional status. Scores for each of the 8 items are summed to give an overall score (out of 40). The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.

    Time frame: Baseline, week 4, week 16

07

Results

Posted Jun 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneQVA149 110/50
Started401
Intent to treat set (itt)338
Completed301
Not completed100
Withdrew: Screen failed24
Withdrew: Adverse event32
Withdrew: Protocol deviation18
Withdrew: Patient withdrew consent12
Withdrew: Lost to follow-up6
Withdrew: Administrative problems6
Withdrew: Abnormal test procedure result1
Withdrew: Unsatisfactory therapeutic effect1

Outcome measures

PrimaryChange From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)

Primary end points: To evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 with tiotropium monotherapy; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks. and to evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 while on treatment with FDC of fluticasone propionate/salmeterol; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks.

Time frame:
16 weeks study
Reported as:
Mean · Liter
Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)
LiterQVA149 110/50 After Flu/SalQVA149 110/50 After Tio
Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)0.17 ± 0.3970.18 ± 0.321
Statistical analysis
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · Descriptive Statistics with 95% CI · Mean difference (final values): 0.17 · 95% CI 0.14 to 0.21The mean change from baseline along with the 95% confidence interval used to assess the precision of the estimate
SecondaryChange From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4

Portable spirometers will be provided to investigators and they will use this device for all of their patient measurements of FEV1 during the trial

Time frame:
Baseline, week 4
Reported as:
Mean · Liter
Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4
LiterQVA149 110/50 After Flu/SalQVA149 110/50 After Tio
Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 40.12 ± 0.3080.14 ± 0.267
Statistical analysis
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · Descriptive Statistics with 95% CI · Mean difference (final values): 0.14 · 95% CI 0.11 to 0.17The mean change from baseline along with the 95% confidence interval used to assess the precision of the estimate
SecondarySingle Point and Change in Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI)

A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). BDI/TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. The BDI was assessed at Baseline, whereas the TDI was assessed at Week 4 and Week 16.

Time frame:
Baseline, Week 4, week 16
Reported as:
Mean · Score
Single Point and Change in Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI)
ScoreQVA149 110/50 After Flu/SalQVA149 110/50 After Tio
BDI week 06.5 ± 2.076.8 ± 2.09
TDI week 42.2 ± 2.722.0 ± 2.38
TDI week 162.9 ± 3.282.4 ± 2.78
Statistical analysis
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · Standard Descriptive Statistics · Mean difference (final values): 2.0 · 95% CI 1.74 to 2.30The estimated mean change from baseline and corresponding 95% confidence intervals will be displayed for each visit.
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · Standard Descriptive Statistics · Mean difference (final values): 2.5 · 95% CI 2.21 to 2.85The estimated mean change from baseline and corresponding 95% confidence intervals will be displayed for each visit
SecondaryChange From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Questionnaire (CAT)

The CAT is an 8 item questionnaire that assesses the impact of COPD on the patient's functional status. Scores for each of the 8 items are summed to give an overall score (out of 40). The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.

Time frame:
Baseline, week 4, week 16
Reported as:
Mean · Score
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Questionnaire (CAT)
ScoreQVA149 110/50 After Flu/SalQVA149 110/50 After Tio
Week 4-5.9 ± 7.55-4.7 ± 5.71
Week 16-8.2 ± 8.34-5.9 ± 6.44
Statistical analysis
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · standard descriptive statistics · Mean difference (final values): -5.0 · 95% CI -5.7 to -4.3The estimated mean change from baseline to Week 4 along with the 95% confidence interval
  • QVA149 110/50 After Flu/Sal vs QVA149 110/50 After Tio · standard descriptive statistics · Mean difference (final values): -6.5 · 95% CI -7.3 to -5.7The estimated mean change from baseline to Week 4 along with the 95% confidence interval

Adverse events

Collected over From week 0 to week 16. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QVA149 110/500/373 (0%)12/373 (3.2%)56/373 (15%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventQVA149 110/50
PneumoniaInfections and infestations4/373
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/373
AnaemiaBlood and lymphatic system disorders1/373
Lymphadenopathy mediastinalBlood and lymphatic system disorders1/373
Cardiac failureCardiac disorders1/373
Cardiac failure congestiveCardiac disorders1/373
Sinus tachycardiaCardiac disorders1/373
Intestinal ischaemiaGastrointestinal disorders1/373
GastroenteritisInfections and infestations1/373
InfluenzaInfections and infestations1/373
Most frequent other events
Most frequent other events
EventQVA149 110/50
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders13/373
Upper respiratory tract infectionInfections and infestations11/373
CoughRespiratory, thoracic and mediastinal disorders10/373
BronchitisInfections and infestations9/373
DyspnoeaRespiratory, thoracic and mediastinal disorders7/373
DyspepsiaGastrointestinal disorders4/373
NauseaGastrointestinal disorders4/373
DizzinessNervous system disorders4/373
HypertensionVascular disorders4/373

Baseline characteristics

The ITT included all patients who received the study treatment and returned for ≥ 1 post baseline visit

Age, Continuous
Age, Continuous(Years)ULTIBRO BREEZHALER
Mean66.1 ± 9.46
Sex: Female, Male
Sex: Female, Male(Participants)ULTIBRO BREEZHALER
Female149
Male189
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ULTIBRO BREEZHALER
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White330
More than one race0
Unknown or Not Reported4
08

Study locations

1 site
  • Novartis Investigative Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
09

References and documents

Publications

  • Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Prefontaine D, McIvor A. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis. 2019 Jan 18;14:249-260. doi: 10.2147/COPD.S185485. eCollection 2019. PubMed 30718952 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Apr 2017, 31 months.

Results were first posted in Jun 2019, 2 years 2 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 31 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2014
First posted
Jul 29, 2014
StartActual
Aug 27, 2014
Primary completionActual
Apr 5, 2017
CompletionActual
Apr 5, 2017
Results first posted
Jun 24, 2019
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02202616
Responsible party
Sponsor
First posted
Jul 29, 2014
Start date
Aug 27, 2014
Primary completion
Apr 5, 2017
Completion
Apr 5, 2017
Results posted
Jun 24, 2019
Last update
Jul 2, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Indacaterol maleate

Start the discussion